CYNOSURE ERASURE LASER

K984517 · Cynosure, Inc. · GEX · Jan 20, 1999 · General, Plastic Surgery

Device Facts

• Record ID: K984517
• Device Name: CYNOSURE ERASURE LASER
• Applicant: Cynosure, Inc.
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Jan 20, 1999
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Erasure laser is used for the treatment of benign vascular and vascular dependent lesions.

Device Story

The Cynosure Erasure Pulse Dye Laser is a surgical laser system designed for the treatment of benign vascular and vascular dependent lesions. The device consists of three primary interconnected sections: a power supply, a water cooling system, and an optical path. It functions by delivering laser energy to target tissues to induce therapeutic biological effects. The device is intended for use by trained healthcare professionals in a clinical setting. By targeting vascular lesions, the laser facilitates treatment of these conditions, potentially improving patient outcomes. The system is operated by a clinician who directs the laser output to the target area based on clinical assessment.

Clinical Evidence

No clinical data provided. Bench testing only.

Technological Characteristics

The device is a pulse dye laser system comprising a power supply, water cooling system, and optical path. It operates as a surgical laser (Product Code GEX, 21 CFR 878.48). No specific materials, software, or connectivity standards are detailed.

Indications for Use

Indicated for the treatment of benign vascular and vascular dependent lesions in patients requiring laser therapy.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• Cynosure PhotoGenica VLS Laser

Submission Summary (Full Text)

{0}------------------------------------------------

JAN 20 1999

## Kay 4517

## 510(K) Summary

Cynosure, Inc. Submitter: 10 Elizabeth Drive Chelmsford, MA 01824 George Cho Contact: Senior Vice President of Medical Technology December 18, 1998 Date Summary Prepared: Erasure Pulse Dye Laser Device Trade Name: Medical Laser System Common Name: Instrument, surgical, powered, laser Classification Name: 79-GEX 21 CFR 878.48 Cynosure PhotoGenica VLS Laser Equivalent Device: The Erasure Laser consists of three interconnected sections: the power Device Description: supply, the water cooling system and the optical path. Benign cutaneous vascular and vascular dependent lesions. Intended Use: The Erasure Laser is substantially equivalent to the Cynosure Comparison: PhotoGenica VLS Laser in terms of treatment wavelengths, pulse duration, pulse energy, and biological effects. Nonclinical Performance Data: None Clinical Performance Data: None The Cynosure Erasure Laser is another safe and effective laser for Conclusion: vascular and vascular dependent lesions. Additional Information: None requested at this time

{1}------------------------------------------------

## DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular emblem with the department's name encircling a stylized image. The image within the circle appears to be an abstract representation of a human figure or a symbol related to health and well-being. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA".

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 20 1999

Mr. George Cho Senior Vice President of Medical Technology Cynosure, Inc. 10 Elizabeth Drive Chelmsford, Massachusetts 01824

Re: K984517

> Trade Name: Cynosure Erasure Pulse Dye Laser Regulatory Class: II Product Code: GEX Dated: December 18, 1998 Received: December 21, 1998

Dear Mr. Cho:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that. through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{2}------------------------------------------------

Page 2 - Mr. George Cho

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Page 1 of 1

Kapus | 510(k) Number (if known):

Device Name: Cynosure Erasure Pulse Dye Laser

Indications For Use:

The Erasure laser is used for the treatment of benign vascular and vascular dependent lesions.

## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| (Division Sign-Off) | |
|-----------------------------------------|---------|
| Division of General Restorative Devices | |
| 510(k) Number | 4984517 |

Image /page/3/Picture/7 description: The image shows the words "Prescription Use" in bold font, followed by the text "(Per 21 CFR 801.109". There is also a symbol to the right of the text. The text is left-aligned and the symbol is on the right side of the image.

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(Optional Format 1-2-96)

-